Zenith Drugs Ltd (ZENITHDRUG) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039174,
    "name": "Zenith Drugs",
    "stock_name": "Zenith Drugs",
    "full_name": "Zenith Drugs Ltd",
    "name_url": "stocks-analysis/zenith-drugs",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "52.15",
    "chg": -0.85,
    "chgp": "-1.6%",
    "dir": -1,
    "prev_price": "53.00",
    "mcapval": "91.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "ZENITHDRUG",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0QWN01013",
    "curr_date": "Dec 15",
    "curr_time": "",
    "bse_nse_vol": 22400,
    "exc_status": "Active",
    "traded_date": "Dec 15, 2025",
    "traded_date_str": "2025 12 15",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/zenith-drugs-10039174-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Zenith Drugs overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zenith-drugs-overvalued-or-undervalued-3713706",
        "imagepath": "",
        "date": "2025-11-19 08:11:30",
        "description": "As of 18 November 2025, Zenith Drugs has moved from a fair to an expensive valuation grade. The company appears to be overvalued at its current price of 57.35, especially when considering its PE ratio of 13.74, EV to EBIT of 14.11, and ROE of 9.98%. These metrics indicate that the stock is trading at a premium compared to its earnings and book value.\n\nIn comparison to its peers, Zenith Drugs' PE ratio is significantly lower than that of Sun Pharma (36.56) and Divi's Lab (69.17), which are both categorized as expensive to very expensive. Meanwhile, Cipla (22.49) and Dr. Reddy's Labs (17.97), which are rated attractive, have more favorable valuations. Additionally, Zenith Drugs has underperformed the Sensex significantly over the past year, with a stock return of -39.05% compared to the Sensex's 10.47%, reinforcing the notion that the stock is currently overvalued...."
      },
      {
        "title": "How has been the historical performance of Zenith Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-zenith-drugs-3704307",
        "imagepath": "",
        "date": "2025-11-15 00:33:05",
        "description": "Answer:\nThe historical performance of Zenith Drugs shows significant growth over the past three years, particularly in revenue and profitability.\n\nBreakdown:\nZenith Drugs has experienced a steady increase in net sales, rising from 91.66 Cr in March 2022 to 114.52 Cr in March 2023, and further to 131.62 Cr in March 2024. Total operating income has mirrored this trend, reaching 131.62 Cr in March 2024. The company's total expenditure has also increased, from 84.82 Cr in March 2022 to 114.71 Cr in March 2024. However, operating profit (PBDIT) has shown a remarkable improvement, climbing from 7.85 Cr in March 2022 to 19.03 Cr in March 2024, indicating enhanced operational efficiency. Profit before tax has similarly surged from 4.41 Cr in March 2022 to 14.74 Cr in March 2024, while profit after tax has increased from 3.13 Cr to 10.94 Cr over the same period. The company's total assets have grown significantly, f..."
      },
      {
        "title": "Why is Zenith Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-zenith-drugs-fallingrising-3587187",
        "imagepath": "",
        "date": "2025-10-02 00:18:24",
        "description": "As of 01-October, Zenith Drugs Ltd is experiencing a price increase, with the current price at 67.90, reflecting a change of 1.3 or 1.95% upward. The stock has shown some positive movement today, outperforming its sector by 0.59%. Additionally, the stock's delivery volume has significantly increased, rising by 213.95% compared to the 5-day average, indicating rising investor participation. However, despite today's gains, the stock has underperformed over the longer term, with a year-to-date decline of 15.97% and a staggering 47.65% drop over the past year.\n\nIn the broader market context, the Sensex has shown a positive return of 5.04% year-to-date, contrasting with Zenith Drugs' significant decline. Over the past week, while Zenith Drugs fell by 1.02%, the Sensex decreased by only 0.88%, suggesting that the stock's recent performance is lagging behind the benchmark. The stock is currently above its 5-day an..."
      },
      {
        "title": "Why is Zenith Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-zenith-drugs-fallingrising-3540547",
        "imagepath": "",
        "date": "2025-09-19 23:42:59",
        "description": "As of 19-Sep, Zenith Drugs Ltd is experiencing a decline in its stock price, currently at 64.45, which reflects a decrease of 0.7 or 1.07%. The stock has underperformed its sector today by 1.34%, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has dropped by 5.36%, and it has seen a significant year-to-date decline of 20.24%. Despite a rise in delivery volume by 90.48% against the 5-day average, there are no positive or negative factors provided that could explain the recent movement in detail.\n\nBroader Market Context: In comparison to the benchmark, the Sensex has shown a positive return of 0.85% over the past week, while Zenith Drugs has significantly lagged behind with its 5.36% decline. This underperformance is indicative of a broader market trend where the stock is not only falling in the short term but also has a troubling longer-t..."
      }
    ],
    "total": 102,
    "sid": "10039174",
    "stock_news_url": "https://www.marketsmojo.com/news/zenith-drugs-10039174"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Zenith Drugs Ltd has declared <strong>5%</strong> dividend, ex-date: 17 Sep 24",
          "dt": "2024-09-17",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Zenith Drugs overvalued or undervalued?

2025-11-19 08:11:30

As of 18 November 2025, Zenith Drugs has moved from a fair to an expensive valuation grade. The company appears to be overvalued at its current price of 57.35, especially when considering its PE ratio of 13.74, EV to EBIT of 14.11, and ROE of 9.98%. These metrics indicate that the stock is trading at a premium compared to its earnings and book value. In comparison to its peers, Zenith Drugs' PE ratio is significantly lower than that of Sun Pharma (36.56) and Divi's Lab (69.17), which are both categorized as expensive to very expensive. Meanwhile, Cipla (22.49) and Dr. Reddy's Labs (17.97), which are rated attractive, have more favorable valuations. Additionally, Zenith Drugs has underperformed the Sensex significantly over the past year, with a stock return of -39.05% compared to the Sensex's 10.47%, reinforcing the notion that the stock is currently overvalued....

How has been the historical performance of Zenith Drugs?

2025-11-15 00:33:05

Answer: The historical performance of Zenith Drugs shows significant growth over the past three years, particularly in revenue and profitability. Breakdown: Zenith Drugs has experienced a steady increase in net sales, rising from 91.66 Cr in March 2022 to 114.52 Cr in March 2023, and further to 131.62 Cr in March 2024. Total operating income has mirrored this trend, reaching 131.62 Cr in March 2024. The company's total expenditure has also increased, from 84.82 Cr in March 2022 to 114.71 Cr in March 2024. However, operating profit (PBDIT) has shown a remarkable improvement, climbing from 7.85 Cr in March 2022 to 19.03 Cr in March 2024, indicating enhanced operational efficiency. Profit before tax has similarly surged from 4.41 Cr in March 2022 to 14.74 Cr in March 2024, while profit after tax has increased from 3.13 Cr to 10.94 Cr over the same period. The company's total assets have grown significantly, f...

Why is Zenith Drugs falling/rising?

2025-10-02 00:18:24

As of 01-October, Zenith Drugs Ltd is experiencing a price increase, with the current price at 67.90, reflecting a change of 1.3 or 1.95% upward. The stock has shown some positive movement today, outperforming its sector by 0.59%. Additionally, the stock's delivery volume has significantly increased, rising by 213.95% compared to the 5-day average, indicating rising investor participation. However, despite today's gains, the stock has underperformed over the longer term, with a year-to-date decline of 15.97% and a staggering 47.65% drop over the past year. In the broader market context, the Sensex has shown a positive return of 5.04% year-to-date, contrasting with Zenith Drugs' significant decline. Over the past week, while Zenith Drugs fell by 1.02%, the Sensex decreased by only 0.88%, suggesting that the stock's recent performance is lagging behind the benchmark. The stock is currently above its 5-day an...

Why is Zenith Drugs falling/rising?

2025-09-19 23:42:59

As of 19-Sep, Zenith Drugs Ltd is experiencing a decline in its stock price, currently at 64.45, which reflects a decrease of 0.7 or 1.07%. The stock has underperformed its sector today by 1.34%, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has dropped by 5.36%, and it has seen a significant year-to-date decline of 20.24%. Despite a rise in delivery volume by 90.48% against the 5-day average, there are no positive or negative factors provided that could explain the recent movement in detail. Broader Market Context: In comparison to the benchmark, the Sensex has shown a positive return of 0.85% over the past week, while Zenith Drugs has significantly lagged behind with its 5.36% decline. This underperformance is indicative of a broader market trend where the stock is not only falling in the short term but also has a troubling longer-t...

View All News